Imorab

Imorab 1000IU Injection is more economical as compared to human rabies immunoglobulin (HRIG) and hence more affordable to patients in developing countries, like India. However, Imorab 1000IU Injection may cause anaphylaxis (a severe, potentially life-threatening allergic reaction), serum sickness and other allergic reactions and thus, physicians are hesitant to use it.

Rabies is a 100% preventable disease. Proper wound management and simultaneous administration of Imorab 1000IU Injection combined with anti-rabies vaccine (ARV) is almost invariably effective in preventing rabies, even after high-risk exposure.

Imorab 1000IU Injection is not required for patients who have previously received a complete vaccination series of rabies.

Imorab 1000IU Injection should be administered into the muscle (the intramuscularly). If a large volume (> 2mL for children or > 5 mL for adults) is required, it is advised to divide the doses and for each dose a different site should be used. The immunoglobulin and the anti-rabies vaccine should be administered at two different sites of the body.

Whether Imorab 1000IU Injection is painful or not depends on your pain tolerance. During your initial treatment, a healthcare professional will put Imorab 1000IU Injection in the area where you were bitten which can be painful. Therefore, you may need a relatively greater amount of Imorab 1000IU Injection may be required to be placed in and around the wound site to ease out your pain and treat infection.